


 (https://correio.anvisa.gov.br/owa)

[The \(perguntas-frequentes\)](#) | [Legislation \(legislacao\)](#) | [Contact \(contato\)](#) | [services \(servicos\)](#) | [Press \(area-de-imprensa\)](#)

MENU

RSS Feed (http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/rss?p_p_cacheability=cacheLevelFull)

Print

NEW ALTERNATIVE

Generic unprecedented approved for the treatment of cancer

First generic everolimo drug will reach the market with lower price than the current reference product.

By: **Ascom / Anvisa**

Posted: 07/24/2018 15:08

Last Modified: 07/26/2018 10:02

Compartilhar 21

Tweeter

Compartilhar

The first generic drug everolimus was approved by Anvisa. The product is indicated for the treatment of several types of cancer, like advanced breast cancer, cancer of kidney, among others.

Because it is generic, the product must reach the market with a price at least 35% lower than the maximum price of the reference product.

Generic everolimo will be produced by India-based Natco Pharma Limited. The owner of the registration in Brazil and responsible for the commercialization of the product in the country is Natcofarma do Brasil Ltda.

Indications approved for everolimo:

- advanced hormone receptor-positive breast cancer;
- advanced neuroendocrine tumors;
- advanced kidney cancer;
- renal angiomyolipoma (a tumor of the kidney) associated with Tuberous Sclerosis Complex (TSC) (in patients over 18 years of age);
- Segs (subependymal giant cell astrocytoma) associated with the Tuberous Sclerosis Complex (TSC).

Want to know Anvisa news first hand? Follow us on Twitter @anvisa_oficial (https://twitter.com/anvisa_oficial) and Facebook @AnvisaOficial (<https://www.facebook.com/AnvisaOficial/>)

Did you find any information wrong or outdated? [click here](#)

cancer (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=c%C3%A2ncer) new generic (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=novo+medicamento+gen%C3%A9rico) generic (<http://portal.anvisa.gov.br/noticias?>)

p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=gen%C3%A9rico+in%C3%A9dito) drug (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=novo+medicamento+gen%C3%A9rico) unpublished (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=gen%C3%A9rico+in%C3%A9dito)

[Back to top!](#)

Barra GovBr (<http://www.acessoinformacao.gov.br/>)